Inflammatory Arthritis

Friday, September 1, 2017

08:00-08:55 Round Table: Patient reported outcomes in inflammatory arthritis
Chairperson Peter Nash, Australia
08:00 Patients reported outcomes value add to rheumatology practice
Helen Benham, Australia
08:15 Role of nurse practitioner
Emma Bavage, Australia
08:30 Practical application in daily practice
Kathleen Tymms, Australia
08:45 Discussion
08:55-09:25 Coffee Break and Poster Viewing
09:25-10:20 Lecture: Dose adjustments in inflammatory arthritis
Chairperson Kevin Pile, Australia
09:25 Rheumatoid arthritis
Tsutomu Takeuchi, Japan
09:45 Ankylosing spondylitis/psoriatic arthritis
Paul Bird, Australia
10:05 Discussion
10:25-11:20 Round Table: First treatment choice in difficult rheumatoid arthritis
Chairperson Tsutoma Takeuchi, Japan
10:25 Tablets
Mark Genovese, USA
10:45 Injection therapy
Boulos Haraoui, Canada
11:05 Discussion
12:25-13:30 Lunch Break and Poster Viewing
13:30-14:25 Round Table: What are the best ways to assess therapies in inflammatory arthritis?
Chairperson Maxime Dougados, France
13:30 Randomised trials
Mark Genovese, USA
13:45 Database studies
Jean-Pierre Raynauld, Canada
14:00 Australian initiatives for Cochrane and clinical trials
Rachelle Buchbinder, Australia
14:15 Discussion
15:00-15:55 Debate: Management of comorbidities in inflammatory arthritis
Chairperson Mark Genovese, USA
15:00 It is the responsibility of the family physician
Kevin Pile, Australia
15:20 Rheumatologists should take the lead
Boulos Haraoui, Canada
15:40 Discussion

Saturday, September 2, 2017

09:05-10:00 Debate: Should spondyloarthritis (SpA) be considered one single entity or should it be split into multiple diseases?
Chairperson Huji Xu, China
09:05 Pro (one entity)
Maxime Dougados, France
09:25 Con (multiple diseases)
Peter Nash, Australia
09:45 Discussion
10:05-11:00 Debate: Biologic choice in psoriatic arthritis/spondylarthropathies
Chairperson Philip Conaghan, UK
10:05 If not anti-IL-17, how do the alternatives stack up?
Matt Brown, Australia
10:25 IL17 blockade should be the first choice in PSA/SA
Peter Nash, Australia
10:45 Discussion
11:00-11:30 Coffee Break and Poster Viewing
11:30-12:25 Round Table: Non-radiographic ankylosing spondylitis
Chairperson Paul Bird, Australia
11:30 Epidemiology, prevalence and diagnosis
Maxime Dougados, France
11:50 Management and progression/prognosis
Matt Brown, Australia
12:10 Discussion
13:30-14:30 Lunch Break and Poster Viewing
14:30-15:25 Lecture: Practical approach to the extra-articular manifestations of rheumatoid arthritis
Chairperson Susanna M. Proudman, Australia
14:30 Interstitial lung disease
Tsutomu Takeuchi, Japan
14:45 Sjögren’s
Maureen Rischmeuller, Australia
15:00 Vasculitis
Stephen Hall, Australia
15:15 Discussion
15:25-15:45 Coffee Break and Poster Viewing
15:45-16:40 Lecture/Round Table: Seronegative rheumatoid arthritis
Chairperson Stephen Hall, Australia
15:45 Is sero-negative rheumatoid arthritis a different entity: Epidemiology, clinical features?
Tore K. Kvien, Norway
16:05 Prognosis and management
Susanna M. Proudman, Australia
16:25 Discussion
16:45-17:15 IA Oral Abstract and Award Presentations
Chairperson Boulos Haraoui, Canada
16:45 Tele-rheumatology in South East Queensland: Evaluating a new model of care and investigation of patient perspectives
Swapna Devadula, Australia
16:55 Real world considerations for the use of biosimilars in rheumatology: What do Australian
physicians think?
Michael Reilly, USA
17:05 Development and evaluation of topical liposomal formulation of diflunisal based on AKBA-phospholipid complex for synergistic and promising efficacy in arthritic conditions
Amanpreet Kaur, India